News | PET Imaging | May 25, 2016

Combining computed bioconductance with PET imaging improves ability to distinguish malignant from benign lesions

China, computed bioconductance, CB, PET, positron emission tomography, lung lesions

May 25, 2016 — Positron emission tomography (PET) is used commonly in the diagnosis of suspected lung cancer. Computed bioconductance (CB) id being investigated as a non-invasive way to predict whether an suspicious abnormality in the lung is benign or malignant. In a new study, researchers found that CB combined with PET before biopsy of suspicious lesions could improve diagnostic effectiveness of potentially cancerous lesions detected by computed tomography (CT) scan.

In this prospective analysis, researchers found CB results combined with PET improved the ability to distinguish malignant from benign conditions compared with PET alone.

"In China, lung cancer is the leading cause of cancer mortality and causes huge health burdens and expense. Adding CB measurement to standard PET scanning could prove to be a useful, non-invasive diagnostic tool for aiding diagnosis of patients with lung cancer" said Dawei Yang, M.D., lead author, Zhongshan Hospital Fudan University in Shanghai, China.

Study results were shared at the Chinese Thoracic Society (CHEST) World Congress 2016, April 15-17 in Shanghai.

For more information: www.journal.publications.chestnet.org


Related Content

News | Radiology Imaging

Feb. 12, 2026 — Siemens Healthineers and Mayo Clinic are expanding their strategic collaboration to enhance patient care ...

Time February 13, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 9, 2026 — MRIguidance, a MedTech company developing BoneMRI, a radiation-free bone imaging solution, has appointed ...

Time February 09, 2026
arrow
Feature | Cardiac Imaging | Kyle Hardner

Advances in coronary CT angiography (CCTA) have reached the point where image quality and AI capabilities are creating ...

Time February 06, 2026
arrow
News | FDA

Jan. 29, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MIM ...

Time February 03, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 27, 2026 — Hyperfine has announced results from the largest data set to date evaluating stroke detection with its ...

Time January 28, 2026
arrow
News | PET Imaging

Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time January 27, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 20, 2026 — Hyperfine, the developer of the first FDA-cleared AI-powered portable MRI system for the brain — the ...

Time January 20, 2026
arrow
News | Radiation Oncology

Jan. 8, 2026 — RefleXion Medical, an external-beam theranostic oncology company, has announced the U.S. Food and Drug ...

Time January 13, 2026
arrow
News | Artificial Intelligence

Dec. 1, 2025 — Researchers at the University of California, Berkeley and University of California, San Francisco have ...

Time December 10, 2025
arrow
News | FDA

Nov. 26, 2025 — a2z Radiology AI has received U.S. FDA clearance for a2z-Unified-Triage, a single device that flags and ...

Time December 03, 2025
arrow
Subscribe Now